{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-007230","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.925279+00:00","generated_at":"2026-05-15T22:34:05.200257+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan","bullets":["$125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.","Total 2026 share repurchase initiative target is ~$200M, funded via existing $225M revolving credit facility.","Since program authorization in May 2025, ~$160M of common stock repurchased to date.","CEO states stock is \"meaningfully undervalued\" relative to business strength and growth trajectory."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-007230","json":"https://secwatch.observer/filing/0001140361-26-007230.json","markdown":"https://secwatch.observer/filing/0001140361-26-007230.md","text":"https://secwatch.observer/filing/0001140361-26-007230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126007230/0001140361-26-007230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126007230/ef20066774_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:34:05.200257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}